Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
Mark W Burns, Eric S Kim Wilmot Cancer Center, University of Rochester, Rochester, NY, USA Abstract: Lung cancer has become one of the leading causes of death in both men and women in the United States, with approximately 230,000 new cases and 160,000 deaths each year. Approximately 80% of lung can...
Main Authors: | Burns MW, Kim ES |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-05-01
|
Series: | Lung Cancer : Targets and Therapy |
Online Access: | http://www.dovepress.com/profile-of-ceritinib-in-the-treatment-of-alk-metastatic-non-small-cell-peer-reviewed-article-LCTT |
Similar Items
-
Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
by: El-Osta H, et al.
Published: (2015-09-01) -
New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
by: Rothschild SI
Published: (2016-05-01) -
Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer
by: K. K. Laktionov, et al.
Published: (2019-06-01) -
Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
by: Kanaan Z, et al.
Published: (2015-04-01) -
Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer
by: Schaefer ES, et al.
Published: (2016-03-01)